{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:58:59Z","timestamp":1793681939159,"version":"4.5.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["AdvCSP-2"],"award-info":[{"award-number":["AdvCSP-2"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["RO1EY025794"],"award-info":[{"award-number":["RO1EY025794"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24EY028767"],"award-info":[{"award-number":["R24EY028767"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["RO1EY025794"],"award-info":[{"award-number":["RO1EY025794"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R24EY028767"],"award-info":[{"award-number":["R24EY028767"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL161087"],"award-info":[{"award-number":["1R01HL161087"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL161087"],"award-info":[{"award-number":["1R01HL161087"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1149"],"award-info":[{"award-number":["CRC 1149"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5<jats:sup>+<\/jats:sup> mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing and engraftment potential, their ability to adaptively respond to inflammatory signals, and their wound healing-promoting efficacy in mouse wound models and human chronic venous ulcers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The angiogenic potential of ABCB5<jats:sup>+<\/jats:sup> MSCs was characterized with respect to angiogenic factor expression at the mRNA and protein level, <jats:italic>in vitro<\/jats:italic> endothelial trans-differentiation and tube formation potential, and perfusion-restoring capacity in a mouse hindlimb ischemia model. Finally, the efficacy and safety of ABCB5<jats:sup>+<\/jats:sup> MSCs for topical adjunctive treatment of chronic, standard therapy-refractory, neuropathic plantar DFUs were assessed in an open-label single-arm clinical trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hypoxic incubation of ABCB5<jats:sup>+<\/jats:sup> MSCs led to posttranslational stabilization of the hypoxia-inducible transcription factor\u00a01<jats:italic>\u03b1<\/jats:italic> (HIF-1<jats:italic>\u03b1<\/jats:italic>) and upregulation of HIF-1<jats:italic>\u03b1<\/jats:italic> mRNA levels. HIF-1<jats:italic>\u03b1<\/jats:italic> pathway activation was accompanied by upregulation of vascular endothelial growth factor (VEGF) transcription and increase in VEGF protein secretion. Upon culture in growth factor-supplemented medium, ABCB5<jats:sup>+<\/jats:sup> MSCs expressed the endothelial-lineage marker CD31, and after seeding on gel matrix, ABCB5<jats:sup>+<\/jats:sup> MSCs demonstrated formation of capillary-like structures comparable with human umbilical vein endothelial cells. Intramuscularly injected ABCB5<jats:sup>+<\/jats:sup> MSCs to mice with surgically induced hindlimb ischemia accelerated perfusion recovery as measured by laser Doppler blood perfusion imaging and enhanced capillary proliferation and vascularization in the ischemic muscles. Adjunctive topical application of ABCB5<jats:sup>+<\/jats:sup> MSCs onto therapy-refractory DFUs elicited median wound surface area reductions from baseline of 59% (full analysis set, <jats:italic>n<\/jats:italic>\u2009=\u200923), 64% (per-protocol set, <jats:italic>n<\/jats:italic>\u2009=\u200920) and 67% (subgroup of responders, <jats:italic>n<\/jats:italic>\u2009=\u200917) at week\u00a012, while no treatment-related adverse events were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present observations identify GMP-manufactured ABCB5<jats:sup>+<\/jats:sup> dermal MSCs as a potential, safe candidate for adjunctive therapy of otherwise incurable DFUs and justify the conduct of a larger, randomized controlled trial to validate the clinical efficacy.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov, NCT03267784, Registered 30 August 2017, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03267784\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03267784<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-022-03156-9","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T18:02:34Z","timestamp":1662400954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers"],"prefix":"10.1186","volume":"13","author":[{"given":"Andreas","family":"Kerstan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Niebergall-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Klingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"J\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hasslacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Daeschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Meyer-Pannwitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Klausmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korinna","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Esterlechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes M.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Ballikaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Waaga-Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis P.","family":"Orgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Y.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ganss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Scharffetter-Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus H.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-4645","authenticated-orcid":false,"given":"Mark A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"3156_CR1","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367\u201375.","journal-title":"N Engl J Med"},{"key":"3156_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/iwj.12404","volume":"13","author":"DC Jupiter","year":"2016","unstructured":"Jupiter DC, Thorud JC, Buckley CJ, Shibuya N. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review. Int Wound J. 2016;13:892\u2013903.","journal-title":"Int Wound J"},{"key":"3156_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13300-018-0536-8","volume":"10","author":"J Xiang","year":"2019","unstructured":"Xiang J, Wang S, He Y, Xu L, Zhang S, Tang Z. Reasonable glycemic control would help wound healing during the treatment of diabetic foot ulcers. Diabetes Ther. 2019;10:95\u2013105.","journal-title":"Diabetes Ther"},{"key":"3156_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/dme.13054","volume":"33","author":"JW Walsh","year":"2016","unstructured":"Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2016;33:1493\u20138.","journal-title":"Diabet Med"},{"key":"3156_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.2337\/dc08-1242","volume":"31","author":"MJ Young","year":"2008","unstructured":"Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995\u20132008: possible impact of aggressive cardiovascular risk management. Diabetes Care. 2008;31:2143\u20137.","journal-title":"Diabetes Care"},{"key":"3156_CR6","doi-asserted-by":"publisher","first-page":"2879809","DOI":"10.1155\/2016\/2879809","volume":"2016","author":"NK Chammas","year":"2016","unstructured":"Chammas NK, Hill RL, Edmonds ME. Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J Diabetes Res. 2016;2016:2879809.","journal-title":"J Diabetes Res"},{"key":"3156_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11883-017-0680-z","volume":"19","author":"I Dietrich","year":"2017","unstructured":"Dietrich I, Braga GA, de Melo FG, da Costa Silva Silva ACC. The diabetic foot as a proxy for cardiovascular events and mortality review. Curr Atheroscler Rep. 2017;19:44.","journal-title":"Curr Atheroscler Rep"},{"key":"3156_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jdiacomp.2014.04.011","volume":"28","author":"D Martins-Mendes","year":"2014","unstructured":"Martins-Mendes D, Monteiro-Soares M, Boyko EJ, Ribeiro M, Barata P, Lima J, et al. The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk. J Diabetes Complications. 2014;28:632\u20138.","journal-title":"J Diabetes Complications"},{"key":"3156_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jdiacomp.2016.11.020","volume":"31","author":"MB Brennan","year":"2017","unstructured":"Brennan MB, Hess TM, Bartle B, Cooper JM, Kang J, Huang ES, et al. Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes. J Diabetes Complicat. 2017;31:556\u201361.","journal-title":"J Diabetes Complicat"},{"key":"3156_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00125-006-0491-1","volume":"50","author":"L Prompers","year":"2007","unstructured":"Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18\u201325.","journal-title":"Diabetologia"},{"key":"3156_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.diabet.2010.10.003","volume":"37","author":"JL Richard","year":"2011","unstructured":"Richard JL, Lavigne JP, Got I, Hartemann A, Malgrange D, Tsirtsikolou D, et al. Management of patients hospitalized for diabetic foot infection: results of the French OPIDIA study. Diabetes Metab. 2011;37:208\u201315.","journal-title":"Diabetes Metab"},{"key":"3156_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/00365548.2013.765589","volume":"45","author":"M Mutluoglu","year":"2013","unstructured":"Mutluoglu M, Sivrioglu AK, Eroglu M, Uzun G, Turhan V, Ay H, et al. The implications of the presence of osteomyelitis on outcomes of infected diabetic foot wounds. Scand J Infect Dis. 2013;45:497\u2013503.","journal-title":"Scand J Infect Dis"},{"key":"3156_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13047-019-0345-y","volume":"12","author":"E Ugwu","year":"2019","unstructured":"Ugwu E, Adeleye O, Gezawa I, Okpe I, Enamino M, Ezeani I. Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study. J Foot Ankle Res. 2019;12:34.","journal-title":"J Foot Ankle Res"},{"key":"3156_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/ijabmr.IJABMR_278_18","volume":"9","author":"A Seth","year":"2019","unstructured":"Seth A, Attri AK, Kataria H, Kochhar S, Seth SA, Gautam N. Clinical profile and outcome in patients of diabetic foot infection. Int J Appl Basic Med Res. 2019;9:14\u20139.","journal-title":"Int J Appl Basic Med Res"},{"key":"3156_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","volume":"13","author":"DG Armstrong","year":"2020","unstructured":"Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020;13:16.","journal-title":"J Foot Ankle Res"},{"key":"3156_CR16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.2337\/dc06-2043","volume":"30","author":"P Ince","year":"2007","unstructured":"Ince P, Game FL, Jeffcoate WJ. Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area. Diabetes Care. 2007;30:660\u20133.","journal-title":"Diabetes Care"},{"key":"3156_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/iwj.12600","volume":"14","author":"CM Zelen","year":"2017","unstructured":"Zelen CM, Orgill DP, Serena T, Galiano R, Carter MJ, DiDomenico LA, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14:307\u201315.","journal-title":"Int Wound J"},{"key":"3156_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.12968\/jowc.2020.29.8.464","volume":"29","author":"G Van Ha","year":"2020","unstructured":"Van Ha G, Amouyal C, Bourron O, Aubert C, Carlier A, Mosbah H, et al. Diabetic foot ulcer management in a multidisciplinary foot centre: one-year healing, amputation and mortality rate. J Wound Care. 2020;29:464\u201371.","journal-title":"J Wound Care"},{"key":"3156_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/wrr.12391","volume":"24","author":"LA Lavery","year":"2016","unstructured":"Lavery LA, Davis KE, Berriman SJ, Braun L, Nichols A, Kim PJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24:112\u201326.","journal-title":"Wound Repair Regen"},{"key":"3156_CR20","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1016\/j.jvs.2015.10.003","volume":"63","author":"A Hingorani","year":"2016","unstructured":"Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63:3s\u201321s.","journal-title":"J Vasc Surg"},{"key":"3156_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.12968\/jowc.2018.27.Sup5.S1","volume":"27","author":"K Ousey","year":"2018","unstructured":"Ousey K, Chadwick P, Jawien A, Tariq G, Nair HKR, L\u00e1zaro-Mart\u00ednez JL, et al. Identifying and treating foot ulcers in patients with diabetes: saving feet, legs and lives. J Wound Care. 2018;27:S1-s52.","journal-title":"J Wound Care"},{"issue":"Suppl 1","key":"3156_CR22","volume":"36","author":"NC Schaper","year":"2020","unstructured":"Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1): e3266.","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"3156_CR23","volume":"36","author":"P Vas","year":"2020","unstructured":"Vas P, Rayman G, Dhatariya K, Driver V, Hartemann A, Londahl M, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020;36(Suppl 1): e3284.","journal-title":"Diabetes Metab Res Rev"},{"key":"3156_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/ijms18071419","volume":"18","author":"UA Okonkwo","year":"2017","unstructured":"Okonkwo UA, DiPietro LA. Diabetes and wound angiogenesis. Int J Mol Sci. 2017;18:1419.","journal-title":"Int J Mol Sci"},{"key":"3156_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/medicina57101072","volume":"57","author":"JL Burgess","year":"2021","unstructured":"Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, Jozic I. Diabetic wound-healing science. Medicina. 2021;57:1072.","journal-title":"Medicina"},{"key":"3156_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/jcm11030889","volume":"11","author":"L Rehak","year":"2022","unstructured":"Rehak L, Giurato L, Meloni M, Panunzi A, Manti GM, Uccioli L. The immune-centric revolution in the diabetic foot: monocytes and lymphocytes role in wound healing and tissue regeneration-a narrative review. J Clin Med. 2022;11:889.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"3156_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/dmrr.2742","volume":"32","author":"SB Catrina","year":"2016","unstructured":"Catrina SB, Zheng X. Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. Diabetes Metab Res Rev. 2016;32(Suppl 1):179\u201385.","journal-title":"Diabetes Metab Res Rev"},{"key":"3156_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1747.2000.00029.x","volume":"115","author":"C Wetzler","year":"2000","unstructured":"Wetzler C, K\u00e4mpfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol. 2000;115:245\u201353.","journal-title":"J Invest Dermatol"},{"key":"3156_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cyto.2011.06.016","volume":"56","author":"R Mirza","year":"2011","unstructured":"Mirza R, Koh TJ. Dysregulation of monocyte\/macrophage phenotype in wounds of diabetic mice. Cytokine. 2011;56:256\u201364.","journal-title":"Cytokine"},{"key":"3156_CR30","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2337\/db12-1450","volume":"62","author":"RE Mirza","year":"2013","unstructured":"Mirza RE, Fang MM, Ennis WJ, Koh TJ. Blocking interleukin-1\u03b2 induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes. Diabetes. 2013;62:2579\u201387.","journal-title":"Diabetes"},{"key":"3156_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db13-0927","volume":"63","author":"RE Mirza","year":"2014","unstructured":"Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes. 2014;63:1103\u201314.","journal-title":"Diabetes"},{"key":"3156_CR32","first-page":"1434","volume":"6","author":"P Bannon","year":"2013","unstructured":"Bannon P, Wood S, Restivo T, Campbell L, Hardman MJ, Mace KA. Diabetes induces stable intrinsic changes to myeloid cells that contribute to chronic inflammation during wound healing in mice. Dis Model Mech. 2013;6:1434\u201347.","journal-title":"Dis Model Mech"},{"key":"3156_CR33","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3390\/molecules26164917","volume":"26","author":"SM Aitcheson","year":"2021","unstructured":"Aitcheson SM, Frentiu FD, Hurn SE, Edwards K, Murray RZ. Skin wound healing: normal macrophage function and macrophage dysfunction in diabetic wounds. Molecules. 2021;26:4917.","journal-title":"Molecules"},{"key":"3156_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1524-475X.2007.00278.x","volume":"15","author":"KA Mace","year":"2007","unstructured":"Mace KA, Yu DH, Paydar KZ, Boudreau N, Young DM. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen. 2007;15:636\u201345.","journal-title":"Wound Repair Regen"},{"key":"3156_CR35","doi-asserted-by":"publisher","first-page":"19426","DOI":"10.1073\/pnas.0805230105","volume":"105","author":"IR Botusan","year":"2008","unstructured":"Botusan IR, Sunkari VG, Savu O, Catrina AI, Gr\u00fcnler J, Lindberg S, et al. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A. 2008;105:19426\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3156_CR36","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.2337\/diabetes.53.12.3226","volume":"53","author":"SB Catrina","year":"2004","unstructured":"Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes. 2004;53:3226\u201332.","journal-title":"Diabetes"},{"key":"3156_CR37","doi-asserted-by":"publisher","first-page":"13505","DOI":"10.1073\/pnas.0906670106","volume":"106","author":"H Thangarajah","year":"2009","unstructured":"Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106:13505\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3156_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11154-019-09492-1","volume":"20","author":"M Zubair","year":"2019","unstructured":"Zubair M, Ahmad J. Role of growth factors and cytokines in diabetic foot ulcer healing: a detailed review. Rev Endocr Metab Disord. 2019;20:207\u201317.","journal-title":"Rev Endocr Metab Disord"},{"key":"3156_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.trsl.2006.11.005","volume":"149","author":"AK Singh","year":"2007","unstructured":"Singh AK, Gudehithlu KP, Patri S, Litbarg NO, Sethupathi P, Arruda JA, et al. Impaired integration of endothelial progenitor cells in capillaries of diabetic wounds is reversible with vascular endothelial growth factor infusion. Transl Res. 2007;149:282\u201391.","journal-title":"Transl Res"},{"key":"3156_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231962","volume":"15","author":"UA Okonkwo","year":"2020","unstructured":"Okonkwo UA, Chen L, Ma D, Haywood VA, Barakat M, Urao N, et al. Compromised angiogenesis and vascular Integrity in impaired diabetic wound healing. PLoS ONE. 2020;15: e0231962.","journal-title":"PLoS ONE"},{"key":"3156_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13287-018-0938-6","volume":"9","author":"L Lopes","year":"2018","unstructured":"Lopes L, Setia O, Aurshina A, Liu S, Hu H, Isaji T, et al. Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther. 2018;9:188.","journal-title":"Stem Cell Res Ther"},{"key":"3156_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/ten.teb.2019.0351","volume":"26","author":"YZ Huang","year":"2020","unstructured":"Huang YZ, Gou M, Da LC, Zhang WQ, Xie HQ. Mesenchymal stem cells for chronic wound healing: current status of preclinical and clinical studies. Tissue Eng Part B Rev. 2020;26:555\u201370.","journal-title":"Tissue Eng Part B Rev"},{"key":"3156_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.addr.2018.07.019","volume":"146","author":"H Cho","year":"2019","unstructured":"Cho H, Blatchley MR, Duh EJ, Gerecht S. Acellular and cellular approaches to improve diabetic wound healing. Adv Drug Deliv Rev. 2019;146:267\u201388.","journal-title":"Adv Drug Deliv Rev"},{"key":"3156_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fcell.2020.00697","volume":"8","author":"D Jiang","year":"2020","unstructured":"Jiang D, Scharffetter-Kochanek K. Mesenchymal stem cells adaptively respond to environmental cues thereby improving granulation tissue formation and wound healing. Front Cell Dev Biol. 2020;8:697.","journal-title":"Front Cell Dev Biol"},{"key":"3156_CR45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13287-021-02397-4","volume":"12","author":"P Gentile","year":"2021","unstructured":"Gentile P, Sterodimas A, Calabrese C, Garcovich S. Systematic review: advances of fat tissue engineering as bioactive scaffold, bioactive material, and source for adipose-derived mesenchymal stem cells in wound and scar treatment. Stem Cell Res Ther. 2021;12:318.","journal-title":"Stem Cell Res Ther"},{"key":"3156_CR46","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/ijms22041538","volume":"22","author":"P Gentile","year":"2021","unstructured":"Gentile P, Garcovich S. Systematic review: adipose-derived mesenchymal stem cells platelet-rich plasma and biomaterials as new regenerative strategies in chronic skin wounds and soft tissue defects. Int J Mol Sci. 2021;22:1538.","journal-title":"Int J Mol Sci"},{"key":"3156_CR47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fimmu.2015.00560","volume":"6","author":"P Mattar","year":"2015","unstructured":"Mattar P, Bieback K. Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells. Front Immunol. 2015;6:560.","journal-title":"Front Immunol"},{"key":"3156_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/14712598.2020.1761322","volume":"20","author":"P Gentile","year":"2020","unstructured":"Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020;20:711\u20136.","journal-title":"Expert Opin Biol Ther"},{"key":"3156_CR49","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6:eaba6884.","journal-title":"Sci Adv"},{"key":"3156_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.10.026","author":"K Singh","year":"2021","unstructured":"Singh K, Maity P, Koroma AK, Basu A, Pandey RK, Beken SV, et al. Angiogenin released from ABCB5(+) stromal precursors improves healing of diabetic wounds by promoting angiogenesis. J Invest Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jid.2021.10.026.","journal-title":"J Invest Dermatol"},{"key":"3156_CR51","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.celrep.2015.08.010","volume":"12","author":"T Schatton","year":"2015","unstructured":"Schatton T, Yang J, Kleffel S, Uehara M, Barthel SR, Schlapbach C, et al. ABCB5 identifies immunoregulatory dermal cells. Cell Rep. 2015;12:1564\u201374.","journal-title":"Cell Rep"},{"key":"3156_CR52","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/stem.2417","volume":"34","author":"D Jiang","year":"2016","unstructured":"Jiang D, Muschhammer J, Qi Y, Kugler A, de Vries JC, Saffarzadeh M, et al. Suppression of neutrophil-mediated tissue damage\u2014a novel skill of mesenchymal stem cells. Stem Cells. 2016;34:2393\u2013406.","journal-title":"Stem Cells"},{"key":"3156_CR53","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/stem.3022","volume":"37","author":"S Vander Beken","year":"2019","unstructured":"Vander Beken S, de Vries JC, Meier-Schiesser B, Meyer P, Jiang D, Sindrilaru A, et al. Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist. Stem Cells. 2019;37:1057\u201374.","journal-title":"Stem Cells"},{"key":"3156_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jcyt.2020.08.012","volume":"23","author":"A Kerstan","year":"2021","unstructured":"Kerstan A, Niebergall-Roth E, Esterlechner J, Schr\u00f6der HM, Gasser M, Waaga-Gasser AM, et al. Ex vivo-expanded highly pure ABCB5(+) mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data. Cytotherapy. 2021;23:165\u201375.","journal-title":"Cytotherapy"},{"key":"3156_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100067","volume":"2","author":"A Kerstan","year":"2022","unstructured":"Kerstan A, Dieter K, Niebergall-Roth E, Dachtler A-K, Kraft K, St\u00fccker M, et al. Allogeneic ABCB5(+) mesenchymal stem cells for treatment-refractory chronic venous ulcers: a phase I\/IIa clinical trial. JID Innov. 2022;2: 100067.","journal-title":"JID Innov"},{"key":"3156_CR56","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13287-020-01987-y","volume":"11","author":"S Ballikaya","year":"2020","unstructured":"Ballikaya S, Sadeghi S, Niebergall-Roth E, Nimtz L, Frindert J, Norrick A, et al. Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP. Stem Cell Res Ther. 2020;11:482.","journal-title":"Stem Cell Res Ther"},{"key":"3156_CR57","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jcyt.2018.12.005","volume":"21","author":"N Tappenbeck","year":"2019","unstructured":"Tappenbeck N, Schr\u00f6der HM, Niebergall-Roth E, Hassinger F, Dehio U, Dieter K, et al. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials. Cytotherapy. 2019;21:546\u201360.","journal-title":"Cytotherapy"},{"key":"3156_CR58","doi-asserted-by":"publisher","first-page":"47156","DOI":"10.1074\/jbc.M308700200","volume":"278","author":"NY Frank","year":"2003","unstructured":"Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003;278:47156\u201365.","journal-title":"J Biol Chem"},{"key":"3156_CR59","unstructured":"International Organization for Standardization. ISO 10993-6:2007. Biological evaluation of medical devices\u2014Part 6: Tests for local effects after implantation. 2007. https:\/\/www.iso.org\/standard\/44789.html. Accessed 13 Apr 2022."},{"key":"3156_CR60","unstructured":"National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management\u2014NICE guideline. 2015. https:\/\/www.nice.org.uk\/guidance\/ng19\/resources\/diabetic-foot-problems-prevention-and-management-pdf-1837279828933. Accessed 20 Dec 2021."},{"key":"3156_CR61","unstructured":"The International Working Group on the Diabetic Foot (IWGDF). IWGDF Practical guidelines on the prevention and management of diabetic foot disease. 2019. https:\/\/iwgdfguidelines.org\/wp-content\/uploads\/2019\/05\/01-IWGDF-practical-guidelines-2019.pdf. Accessed 20 Dec 2021."},{"key":"3156_CR62","first-page":"267","volume":"23","author":"ME Wendelken","year":"2011","unstructured":"Wendelken ME, Berg WT, Lichtenstein P, Markowitz L, Comfort C, Alvarez OM. Wounds measured from digital photographs using photodigital planimetry software: validation and rater reliability. Wounds. 2011;23:267\u201375.","journal-title":"Wounds"},{"key":"3156_CR63","unstructured":"Romanelli M, Vowden K, Weir D. Exudate management made easy. 2010. https:\/\/www.woundsinternational.com\/resources\/details\/exudate-management-made-easy. Accessed 20 Dec 2021."},{"key":"3156_CR64","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1097\/SAP.0000000000001417","volume":"80","author":"DP Perrault","year":"2018","unstructured":"Perrault DP, Bramos A, Xu X, Shi S, Wong AK. Local Administration of interleukin-1 receptor antagonist improves diabetic wound healing. Ann Plast Surg. 2018;80:S317\u201321.","journal-title":"Ann Plast Surg"},{"key":"3156_CR65","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s42003-021-01913-9","volume":"4","author":"JL Tan","year":"2021","unstructured":"Tan JL, Lash B, Karami R, Nayer B, Lu Y-Z, Piotto C, et al. Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist. Commun Biol. 2021;4:422.","journal-title":"Commun Biol"},{"key":"3156_CR66","doi-asserted-by":"publisher","first-page":"695e","DOI":"10.1097\/PRS.0000000000003072","volume":"139","author":"D Duscher","year":"2017","unstructured":"Duscher D, Januszyk M, Maan ZN, Whittam AJ, Hu MS, Walmsley GG, et al. Comparison of the hydroxylase inhibitor dimethyloxalylglycine and the iron chelator deferoxamine in diabetic and aged wound healing. Plast Reconstr Surg. 2017;139:695e\u2013706e.","journal-title":"Plast Reconstr Surg"},{"key":"3156_CR67","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-021-23448-7","volume":"12","author":"G Li","year":"2021","unstructured":"Li G, Ko C-N, Li D, Yang C, Wang W, Yang G-J, et al. A small molecule HIF-1\u03b1 stabilizer that accelerates diabetic wound healing. Nat Commun. 2021;12:3363.","journal-title":"Nat Commun"},{"key":"3156_CR68","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0002-9440(10)63754-6","volume":"164","author":"RD Galiano","year":"2004","unstructured":"Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935\u201347.","journal-title":"Am J Pathol"},{"key":"3156_CR69","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s11095-013-1118-0","volume":"30","author":"MS Akash","year":"2013","unstructured":"Akash MS, Rehman K, Chen S. IL-1Ra and its delivery strategies: inserting the association in perspective. Pharm Res. 2013;30:2951\u201366.","journal-title":"Pharm Res"},{"key":"3156_CR70","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fcell.2020.00638","volume":"8","author":"A Nurkesh","year":"2020","unstructured":"Nurkesh A, Jaguparov A, Jimi S, Saparov A. Recent advances in the controlled release of growth factors and cytokines for improving cutaneous wound healing. Front Cell Dev Biol. 2020;8:638.","journal-title":"Front Cell Dev Biol"},{"key":"3156_CR71","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1091\/mbc.e10-07-0617","volume":"22","author":"S Chamboredon","year":"2011","unstructured":"Chamboredon S, Ciais D, Desroches-Castan A, Savi P, Bono F, Feige JJ, et al. Hypoxia-inducible factor-1alpha mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Mol Biol Cell. 2011;22:3366\u201378.","journal-title":"Mol Biol Cell"},{"key":"3156_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044468","volume":"7","author":"NA Hofmann","year":"2012","unstructured":"Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Rohban R, et al. Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. PLoS ONE. 2012;7: e44468.","journal-title":"PLoS ONE"},{"key":"3156_CR73","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/stem.3356","volume":"39","author":"J Riedl","year":"2021","unstructured":"Riedl J, Pickett-Leonard M, Eide C, Kluth MA, Ganss C, Frank NY, et al. ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment. Stem Cells. 2021;39:897\u2013903.","journal-title":"Stem Cells"},{"key":"3156_CR74","unstructured":"Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). Guideline on human cell-based medicinal products (EMEA\/CHMP\/410869\/2006). 2008. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003894.pdf. Accessed 12 Apr 2022."},{"key":"3156_CR75","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds \u2013 Developing Products for Treatment. 2006. https:\/\/www.fda.gov\/media\/71278\/download. Accessed 12 Apr 2022."},{"key":"3156_CR76","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ymthe.2017.06.004","volume":"25","author":"DJ Prockop","year":"2017","unstructured":"Prockop DJ, Oh JY, Lee RH. Data against a common assumption: xenogeneic mouse models can be used to assay suppression of immunity by human MSCs. Mol Ther. 2017;25:1748\u201356.","journal-title":"Mol Ther"},{"key":"3156_CR77","doi-asserted-by":"publisher","first-page":"8833725","DOI":"10.1155\/2020\/8833725","volume":"2020","author":"C S\u00e1vio-Silva","year":"2020","unstructured":"S\u00e1vio-Silva C, Beyerstedt S, Soinski-Sousa PE, Casaro EB, Balby-Rocha MTA, Simpl\u00edcio-Filho A, et al. Mesenchymal stem cell therapy for diabetic kidney disease: a review of the studies using syngeneic, autologous, allogeneic, and xenogeneic cells. Stem Cells Int. 2020;2020:8833725.","journal-title":"Stem Cells Int"},{"key":"3156_CR78","doi-asserted-by":"publisher","first-page":"963689720954140","DOI":"10.1177\/0963689720954140","volume":"29","author":"KC Lin","year":"2020","unstructured":"Lin KC, Yeh JN, Chen YL, Chiang JY, Sung PH, Lee FY, et al. Xenogeneic and allogeneic mesenchymal stem cells effectively protect the lung against ischemia-reperfusion injury through downregulating the inflammatory, oxidative stress, and autophagic signaling pathways in rat. Cell Transplant. 2020;29:963689720954140.","journal-title":"Cell Transplant"},{"key":"3156_CR79","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.12968\/jowc.2019.28.Sup3a.S1","volume":"23","author":"L Atkin","year":"2019","unstructured":"Atkin L, Bu\u0107ko Z, Conde Montero E, Cutting K, Moffatt C, Probst A, et al. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care. 2019;23:S1-s50.","journal-title":"J Wound Care"},{"key":"3156_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1000-1948(08)60031-3","volume":"23","author":"L Debin","year":"2008","unstructured":"Debin L, Youzhao J, Ziwen L, Xiaoyan L, Zhonghui Z, Bing C. Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. J Med Coll PLA. 2008;23:106\u201315.","journal-title":"J Med Coll PLA"},{"key":"3156_CR81","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.fas.2020.08.002","volume":"27","author":"E Uzun","year":"2021","unstructured":"Uzun E, G\u00fcney A, G\u00f6nen ZB, \u00d6zkul Y, Kafadar \u0130H, G\u00fcnay M, et al. Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I\/2 safety study. Foot Ankle Surg. 2021;27:636\u201342.","journal-title":"Foot Ankle Surg"},{"key":"3156_CR82","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/db18-0699","volume":"68","author":"KC Moon","year":"2019","unstructured":"Moon KC, Suh HS, Kim KB, Han SK, Young KW, Lee JW, et al. Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. Diabetes. 2019;68:837\u201346.","journal-title":"Diabetes"},{"key":"3156_CR83","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/iwj.13433","volume":"17","author":"OJ Smith","year":"2020","unstructured":"Smith OJ, Leigh R, Kanapathy M, Macneal P, Jell G, Hachach-Haram N, et al. Fat grafting and platelet-rich plasma for the treatment of diabetic foot ulcers: A feasibility-randomised controlled trial. Int Wound J. 2020;17:1578\u201394.","journal-title":"Int Wound J"},{"key":"3156_CR84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1524-475X.2010.00593.x","volume":"18","author":"SK Han","year":"2010","unstructured":"Han SK, Kim HR, Kim WK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010;18:342\u20138.","journal-title":"Wound Repair Regen"},{"key":"3156_CR85","unstructured":"Driver VR, Hanft J, Fylling CP, Beriou JM. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52:68\u201370, 2, 4 passim."},{"key":"3156_CR86","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00268-019-05316-0","volume":"44","author":"A Elsaid","year":"2020","unstructured":"Elsaid A, El-Said M, Emile S, Youssef M, Khafagy W, Elshobaky A. Randomized controlled trial on autologous platelet-rich plasma versus saline dressing in treatment of non-healing diabetic foot ulcers. World J Surg. 2020;44:1294\u2013301.","journal-title":"World J Surg"},{"key":"3156_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7547\/19-149","volume":"111","author":"A Gupta","year":"2021","unstructured":"Gupta A, Channaveera C, Sethi S, Ranga S, Anand V. Efficacy of Intralesional platelet-rich plasma in diabetic foot ulcer. J Am Podiatr Med Assoc. 2021;111:7.","journal-title":"J Am Podiatr Med Assoc"},{"key":"3156_CR88","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.avsg.2021.10.061","volume":"82","author":"EM Hossam","year":"2022","unstructured":"Hossam EM, Alserr AHK, Antonopoulos CN, Zaki A, Eldaly W. Autologous platelet rich plasma promotes the healing of non-ischemic diabetic foot ulcers. A randomized controlled trial. Ann Vasc Surg. 2022;82:165\u201371.","journal-title":"Ann Vasc Surg"},{"key":"3156_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.25270\/wnds\/2022.3642","volume":"33","author":"YA Orban","year":"2022","unstructured":"Orban YA, Soliman MA, Hegab YH, Alkilany MM. Autologous platelet-rich plasma vs conventional dressing in the management of chronic diabetic foot ulcers. Wounds. 2022;33:36\u201342.","journal-title":"Wounds"},{"key":"3156_CR90","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/jcm8091486","volume":"8","author":"B De Angelis","year":"2019","unstructured":"De Angelis B, Autilio M, D\u2019Orlandi F, Pepe G, Garcovich S, Scioli MG, et al. Wound healing: in vitro and in vivo evaluation of a bio-functionalized scaffold based on hyaluronic acid and platelet-rich plasma in chronic ulcers. J Clin Med. 2019;8:1486.","journal-title":"J Clin Med"},{"key":"3156_CR91","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/PRS.0b013e3181cb6589","volume":"125","author":"SH Jeong","year":"2010","unstructured":"Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg. 2010;125:944\u201352.","journal-title":"Plast Reconstr Surg"},{"key":"3156_CR92","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/iwj.13646","volume":"19","author":"L Manning","year":"2022","unstructured":"Manning L, Ferreira IB, Gittings P, Hiew J, Ryan E, Baba M, et al. Wound healing with \u201cspray-on\u201d autologous skin grafting (ReCell) compared with standard care in patients with large diabetes-related foot wounds: an open-label randomised controlled trial. Int Wound J. 2022;19:470\u201381.","journal-title":"Int Wound J"},{"key":"3156_CR93","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/iwj.13759","volume":"19","author":"DG Armstrong","year":"2022","unstructured":"Armstrong DG, Galiano RD, Orgill DP, Glat PM, Carter MJ, Di Domenico LA, et al. Multi-centre prospective randomised controlled clinical trial to evaluate a bioactive split thickness skin allograft vs standard of care in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:932\u201344.","journal-title":"Int Wound J"},{"key":"3156_CR94","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2337\/diacare.26.6.1701","volume":"26","author":"WA Marston","year":"2003","unstructured":"Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26:1701\u20135.","journal-title":"Diabetes Care"},{"key":"3156_CR95","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/diacare.24.2.290","volume":"24","author":"A Veves","year":"2001","unstructured":"Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290\u20135.","journal-title":"Diabetes Care"},{"key":"3156_CR96","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1534734609331597","volume":"8","author":"M Edmonds","year":"2009","unstructured":"Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8:11\u20138.","journal-title":"Int J Low Extrem Wounds"},{"key":"3156_CR97","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/iwj.12566","volume":"13","author":"CM Zelen","year":"2016","unstructured":"Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13:272\u201382.","journal-title":"Int Wound J"},{"key":"3156_CR98","first-page":"230","volume":"15","author":"S Lipkin","year":"2003","unstructured":"Lipkin S, Chaikof E, Isseroff Z, Silverstein P. Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers: Results of a multicenter pilot trial. Wounds. 2003;15:230\u20136.","journal-title":"Wounds"},{"key":"3156_CR99","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/iwj.12329","volume":"11","author":"LA Lavery","year":"2014","unstructured":"Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, et al. The efficacy and safety of Grafix(\u00ae) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11:554\u201360.","journal-title":"Int Wound J"},{"key":"3156_CR100","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/sctm.18-0074","volume":"7","author":"AI Caplan","year":"2018","unstructured":"Caplan AI. Cell-based therapies: the nonresponder. Stem Cells Transl Med. 2018;7:762\u20136.","journal-title":"Stem Cells Transl Med"},{"key":"3156_CR101","first-page":"1531","volume":"136","author":"DJ Margolis","year":"2000","unstructured":"Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol. 2000;136:1531\u20135.","journal-title":"Arch Dermatol"},{"key":"3156_CR102","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2337\/diacare.25.10.1835","volume":"25","author":"DJ Margolis","year":"2002","unstructured":"Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care. 2002;25:1835\u20139.","journal-title":"Diabetes Care"},{"key":"3156_CR103","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.amjmed.2003.06.006","volume":"115","author":"DJ Margolis","year":"2003","unstructured":"Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627\u201331.","journal-title":"Am J Med"},{"key":"3156_CR104","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00125-008-0940-0","volume":"51","author":"L Prompers","year":"2008","unstructured":"Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. EURODIALE Study Diabetologia. 2008;51:747\u201355.","journal-title":"EURODIALE Study Diabetologia"},{"key":"3156_CR105","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcjd.2016.06.007","volume":"41","author":"I Roth-Albin","year":"2017","unstructured":"Roth-Albin I, Mai SHC, Ahmed Z, Cheng J, Choong K, Mayer PV. Outcomes following advanced wound care for diabetic foot ulcers: a canadian study. Can J Diabetes. 2017;41:26\u201332.","journal-title":"Can J Diabetes"},{"key":"3156_CR106","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/wound.2015.0668","volume":"5","author":"CE Fife","year":"2016","unstructured":"Fife CE, Horn SD, Smout RJ, Barrett RS, Thomson B. A predictive model for diabetic foot ulcer outcome: the wound healing index. Adv Wound Care (New Rochelle). 2016;5:279\u201387.","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"3156_CR107","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13047-020-00386-z","volume":"13","author":"T Tong","year":"2020","unstructured":"Tong T, Yang C, Tian W, Liu Z, Liu B, Cheng J, et al. Phenotypes and outcomes in middle-aged patients with diabetic foot ulcers: a retrospective cohort study. J Foot Ankle Res. 2020;13:24.","journal-title":"J Foot Ankle Res"},{"key":"3156_CR108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12020-020-02431-0","volume":"71","author":"C Gazzaruso","year":"2021","unstructured":"Gazzaruso C, Gallotti P, Pujia A, Montalcini T, Giustina A, Coppola A. Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study. Endocrine. 2021;71:59\u201368.","journal-title":"Endocrine"},{"key":"3156_CR109","doi-asserted-by":"publisher","first-page":"22936","DOI":"10.3402\/dfa.v5.22936","volume":"5","author":"A Wang","year":"2014","unstructured":"Wang A, Sun X, Wang W, Jiang K. A study of prognostic factors in Chinese patients with diabetic foot ulcers. Diabet Foot Ankle. 2014;5:22936.","journal-title":"Diabet Foot Ankle."},{"key":"3156_CR110","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/JMDH.S194969","volume":"12","author":"LMA Dutra","year":"2019","unstructured":"Dutra LMA, Melo MC, Moura MC, Leme LAP, De Carvalho MR, Mascarenhas AN, et al. Prognosis of the outcome of severe diabetic foot ulcers with multidisciplinary care. J Multidiscip Healthc. 2019;12:349\u201359.","journal-title":"J Multidiscip Healthc"},{"key":"3156_CR111","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7547\/15-176","volume":"107","author":"L Vella","year":"2017","unstructured":"Vella L, Gatt A, Formosa C. Does baseline hemoglobin A(1c) level predict diabetic foot ulcer outcome or wound healing time? J Am Podiatr Med Assoc. 2017;107:272\u20139.","journal-title":"J Am Podiatr Med Assoc"},{"key":"3156_CR112","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.2337\/db20-0188","volume":"69","author":"G Theocharidis","year":"2020","unstructured":"Theocharidis G, Baltzis D, Roustit M, Tellechea A, Dangwal S, Khetani RS, et al. Integrated skin transcriptomics and serum multiplex assays reveal novel mechanisms of wound healing in diabetic foot ulcers. Diabetes. 2020;69:2157\u201369.","journal-title":"Diabetes"},{"key":"3156_CR113","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/wrr.12564","volume":"25","author":"DJ Margolis","year":"2017","unstructured":"Margolis DJ, Hampton M, Hoffstad O, Mala DS, Mirza Z, Woltereck D, et al. NOS1AP genetic variation is associated with impaired healing of diabetic foot ulcers and diminished response to healing of circulating stem\/progenitor cells. Wound Repair Regen. 2017;25:733\u20136.","journal-title":"Wound Repair Regen"},{"key":"3156_CR114","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/bjs.6689","volume":"96","author":"KA Mir","year":"2009","unstructured":"Mir KA, Pugazhendhi S, Paul MJ, Nair A, Ramakrishna BS. Heat-shock protein 70 gene polymorphism is associated with the severity of diabetic foot ulcer and the outcome of surgical treatment. Br J Surg. 2009;96:1205\u20139.","journal-title":"Br J Surg"},{"key":"3156_CR115","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11892-018-0970-z","volume":"18","author":"FM Davis","year":"2018","unstructured":"Davis FM, Kimball A, Boniakowski A, Gallagher K. Dysfunctional wound healing in diabetic foot ulcers: new crossroads. Curr Diab Rep. 2018;18:2.","journal-title":"Curr Diab Rep"},{"key":"3156_CR116","first-page":"33","volume":"L276","author":"European Parliament and Council of the European Union","year":"2010","unstructured":"European Parliament and Council of the European Union. Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off J Eur Union. 2010;L276:33\u201379.","journal-title":"Off J Eur Union"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03156-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-03156-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03156-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T19:07:45Z","timestamp":1662404865000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-03156-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-03156-9","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Skin samples were obtained in accordance with the German Medicines Act (\u201cArzneimittelgesetz\u201d) and the German Act on Organ and Tissue Donation, Removal and Transplantation (\u201cTransplantationsgesetz\u201d) and its amending tissue regulation (TPG-GewV) as discard tissues from plastic surgeries from donors who had given written informed donor consent. All animal experiments were performed by two specialized contract research organizations complying with the requirements defined in European regulations [] and the applicable national (French and German) animal welfare legislations. The experimentation procedures had been approved by the Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur de la Recherche et de l\u2019Innovation, France (APAFIS 2015090212419040), and the Brandenburg State Office for Environment, Health and Consumer Protection, Germany (V3-2347-A-13-8-2011), respectively. The clinical trial was conducted according to the principles of the Helsinki Declaration and Good Clinical Practice. The protocol and all other relevant documents were approved by the local independent ethics committees (lead committee: Ethics Committee at the University of W\u00fcrzburg, W\u00fcrzburg, Germany; reference number 64\/17_ff-sc) and the competent regulatory authority (Paul Ehrlich Institute, Langen, Germany; reference number 3034\/01). Prior to any trial-related activities or procedures, all patients gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have consented to publication of their data and images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MHF and NYF are inventors or co-inventors of US and international patents assigned to Brigham and Women\u2019s Hospital and\/or Boston Children\u2019s Hospital (Boston, MA, USA), licensed to TICEBA GmbH (Heidelberg, Germany) and RHEACELL GmbH & Co. KG (Heidelberg, Germany). MHF and KSK serve as scientific advisors to TICEBA and RHEACELL and participate in corporate-sponsored research collaborations with RHEACELL. ENR, SK, JE, SS and SB are employees of TICEBA. KD, KK and HMS are employees of RHEACELL. CG is CEO, and MAK is CSO of TICEBA and RHEACELL. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"455"}}